维格列汀对新诊断超重2型糖尿病患者炎症因子的影响研究  

Effects of Vildagliptin on Inflammatory Factors in Overweight Patients with Newly Diagnosed Type 2 Diabetes

作　　者：李彦[1] 张先祥[1] 罗涌[1] 王怡[1] 王邦琼[1] 阳皓[1] 徐伟[1] 

机构地区：[1]重庆三峡中心医院内分泌科,重庆404000

出　　处：《中国药房》2013年第26期2449-2452,共4页China Pharmacy

摘　　要：目的:观察维格列汀对新诊断超重2型糖尿病患者炎症因子的影响。方法:将新诊断超重2型糖尿病患者34例,随机分为维格列汀组(18例)与吡格列酮组(16例),均给予二甲双胍1.0g/d,分别给予维格列汀100mg/d,吡格列酮8mg/d,疗程12周。观察两组患者治疗前后的炎症因子水平、血糖控制情况、其他代谢指标的变化和不良事件的发生情况。结果:与治疗前比较,两组患者治疗后校正的糖化血红蛋白(HbA1c)平均降幅差异无统计学意义(P>0.05);与吡格列酮组比较,维格列汀组C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、内脏脂肪因子降低,脂联素升高更为显著(P<0.01),体质量下降更为显著(P<0.05);维格列汀组的胃肠道不良事件(16.67%)多于吡格列酮组(12.50%)。结论:对于新诊断超重2型糖尿病患者,维格列汀降低HbA1c的作用与吡格列酮相似,对炎症因子(CRP、TNF-α、IL-6、脂联素、内脏脂肪因子)改善更为明显,可能成为胰岛素抵抗治疗新的切入点。OBJECTIVE：To observe the effects of vildagliptin on inflammatory factors in overweight patients with newly diagnosed type 2 diabetes. METHODS：34 overweight patients with newly diagnosed type 2 diabeties were randomly divided into vildagliptin group（18 cases）and pioglitazone group（16 cases）. Both were given metformin（1.0 g/d）,and then were treated by vilda-gliptin（100 mg/d）and pioglitazone（8 mg/d）for 12 weeks,respectively. The inflammatory factors level,blood glucose control,other metabolism index and adverse events were observed in 2 groups before and after treatment. RESULTS：Compared with before treatment,there was no statistical significance in average decrease of HbA 1 c between 2 groups after treatment（P0.05）. Compared with pioglitazone group,the levels of CRP,TNF-α,IL-6 and visceral fat factor were reduced while adiponectin and body weight was increased significantly in vildagliptin group （P0.01）;the incidences of gastrointestinal adverse events were higher in vildagliptin group（16.67%）than in pioglitazone group（12.50%）. CONCLUSIONS：For the overweight patients with newly diagnosed type 2 diabetes,vildagliptin shows similar effect as pioglitazone on reducing HbA 1 c,but is more efficient in improving inflammatory factors （CRP,TNF-α,IL-6,adiponectin and visceral fat factor）. It may be a new approach to the treatment for insulin resistance.

关 键 词：2型糖尿病 维格列汀 吡格列酮 炎症因子 

分 类 号：R977.15[医药卫生—药品] R969.4[医药卫生—药学]